Neurohormones in heart failure: Predicting outcomes, optimizing care

European Heart Journal

Volumn 25, Issue 4, 2004, Pages 281-282

  Givertz, Michael M ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; NEUROHORMONE;

EDITORIAL; HEART FAILURE; HUMAN; OUTCOMES RESEARCH; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

BIOLOGICAL MARKERS; HEART FAILURE, CONGESTIVE; HUMANS; NEUROTRANSMITTER AGENTS; PROGNOSIS;

EID: 1542316249     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2003.12.013     Document Type: Editorial

References (8)

1. Latini R, Masson S, Anand I et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004;25:292-9.
2. Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. N Engl J Med 1962;267:650-4.
3. Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
4. Anand IS, Fisher LD, Chiang YT et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-83.
5. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-22.
6. Richards AM, Doughty R, Nicholls MG et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 1999;99:786-92.
7. Cheng V, Kazanagra R, Garcia A et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardial 2001;37:386-91.
8. Latini R, Masson S, Anand I et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106:2454-8.